13.10.2024, 862 Zeichen

Marinomed: Marinomed Biotech AG has published clinical data from the phase II dose-finding clinical trial evaluating the efficacy of Tacrosolv eye drops in patients with allergic rhinoconjunctivitis in the peer-reviewed “Clinical Ophthalmology” journal. The placebo-controlled allergen challenge trial assessed the efficacy and safety of two different doses of Tacrosolv. The results show that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus) significantly reduced ocular symptoms of allergic conjunctivitis, and surprisingly, also the associated nasal allergy symptoms. Remarkably, these results were achieved with a dose that is 20-fold lower than that of the only Tacrolimus eye drop product currently on the market.
Marinomed Biotech: weekly performance: 0.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/10/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1106: ATX zu Mittag 4 Prozent im Minus, ein fehlendes Listing bzw, warum mir diese Marktphase in die Hände spielt

Bildnachweis

Aktien auf dem Radar:Bawag, FACC, RHI Magnesita, Addiko Bank, Kapsch TrafficCom, Austriacard Holdings AG, AT&S, ATX, ATX TR, voestalpine, Porr, ATX NTR, Erste Group, RBI, Uniqa, Lenzing, VIG, DO&CO, Andritz, Amag, EuroTeleSites AG, Marinomed Biotech, Bajaj Mobility AG, ATX Prime, EVN, Flughafen Wien, Mayr-Melnhof, Palfinger, Polytec Group, Rath AG, RWT AG.

---